News Ticker

[ October 6, 2026 ] City of Hope Names New Presidents of Cancer Centers in Arizona and Atlanta Los Angeles Biotech News
[ October 6, 2026 ] MidFirst Bank Donates $35,000 to The Heart Foundation to Support Heart Disease Research and Awareness Los Angeles Biotech News
[ October 6, 2026 ] New World Medical Receives MDR Certification for Ahmed® Glaucoma Valve, Ahmed ClearPath®, and KDB GLIDE® Los Angeles Biotech News
[ October 6, 2026 ] Infleqtion, Honeywell Aerospace and UC Santa Barbara Collaborate to Accelerate Miniaturization and Manufacturability of Quantum Hardware Los Angeles Biotech News
[ October 6, 2026 ] Prostate Cancer Foundation Honors Mary-Ellen Taplin, MD, with the 2026 PCF Women in Science Lifetime Achievement Award Los Angeles Biotech News

LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL

February 14, 2022 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off

THOUSAND OAKS, Calif.: THOUSAND OAKS, Calif., Feb. 14, 2022 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)*. The data will be presented at the monthly…

Copyright © 2026 Biotech Networks, LLC